CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
INKmunebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06056791
NCT06056791Phase 2Completed
CompareCT.gov

An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Inmune Bio, Inc.·interventional·Posted Sep 28, 2023·Updated Feb 27, 2026

In Brief

A Phase 2 clinical trial evaluating INKmune for Cancer and 2 related conditions. Completed, enrolled 12 participants across 8 sites.

Detailed Summary

This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedSep 28, 2023
Enrollment StartNov 30, 2023
Primary CompletionSep 10, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 2.8 years ago

Interventions

INKmunebiological

INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent that does not require donor matching.